Ara
Toplam kayıt 3, listelenen: 1-3
The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer
(Springer, 2020)
Introduction: Although several clinical factors which show the benefit of adjuvant chemotherapy (AC) in early-stage colon cancer use for evaluating the risk of relapse, there is no consensus on which risk factors are more ...
The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study
(Springer, 2021)
Purpose Colorectal cancer is the third leading diagnosis accounting for nearly 10% of all new cancers worldwide. The distinct features among BRAF mutant colorectal cancers make these tumor groups hard to treat for oncologists. ...
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
(Future Medicine Ltd., 2023)
Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative ...